J 2022

Early-onset pulmonary and cutaneous vasculitis driven by constitutively active SRC-family kinase HCK

KANDEROVA, Veronika, Tamara SVOBODOVA, Simon BORNA, Martina FEJTKOVA, Vendula MARTINU et. al.

Basic information

Original name

Early-onset pulmonary and cutaneous vasculitis driven by constitutively active SRC-family kinase HCK

Authors

KANDEROVA, Veronika, Tamara SVOBODOVA, Simon BORNA, Martina FEJTKOVA, Vendula MARTINU, Jana PADEROVA, Michael SVATON, Jarmila KRALOVA, Eva FRONKOVA, Adam KLOCPERK, Stepanka PRUHOVA, Min Ae LEE-KIRSCH, Ludmila HORNOFOVA, Miroslav KOBLIZEK, Petr NOVAK, Olga ZIMMERMANNOVA, Zuzana PARACKOVA, Anna SEDIVA, Tomas KALINA, Ales JANDA, Jana KAYSEROVA, Marcela DVORAKOVA, Milan MACEK, Petr POHUNEK, Petr SEDLACEK, Ashleigh POH, Matthias ERNST, Tomas BRDICKA, Ondrej HRUSAK and Jan LEBL

Edition

Journal of allergy and clinical immunology, New York, Mosby-Elsevier, 2022, 0091-6749

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30102 Immunology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 14.200

RIV identification code

RIV/00216224:14740/22:00128769

Organization unit

Central European Institute of Technology

UT WoS

000820784100013

Keywords in English

SRC-family kinase; hematopoietic cell kinase; inborn error of immunity; pulmonary hemorrhage; cutaneous vasculitis; autoinflammation; inflammatory cytokines; reactive oxygen species; ruxolitinib

Tags

Tags

International impact, Reviewed
Změněno: 5/4/2023 10:44, Mgr. Pavla Foltynová, Ph.D.

Abstract

V originále

Background: Inborn errors of immunity are genetic disorders characterized by various degrees of immune dysregulation that can manifest as immune deficiency, autoimmunity, or autoinflammation. The routine use of next-generation sequencing in the clinic has facilitated the identification of an ever-increasing number of inborn errors of immunity, revealing the roles of immunologically important genes in human pathologies. However, despite this progress, treatment is still extremely challenging. Objective: We sought to report a new monogenic autoinflammatory disorder caused by a de novo activating mutation, p.Tyr515*, in hematopoietic cell kinase (HCK). The disease is characterized by cutaneous vasculitis and chronic pulmonary inflammation that progresses to fibrosis. Methods: Whole-exome sequencing, Sanger sequencing, mass spectrometry, and western blotting were performed to identify and characterize the pathogenic HCK mutation. Dysregulation of mutant HCK was confirmed ex vivo in primary cells and in vitro in transduced cell lines. Results: Mutant HCK lacking the C-terminal inhibitory tyrosine Tyr522 exhibited increased kinase activity and enhanced myeloid cell priming, migration and effector functions, such as production of the inflammatory cytokines IL-1 beta, IL-6, IL-8, and TNF-alpha, and production of reactive oxygen species. These aberrant functions were reflected by inflammatory leukocyte infiltration of the lungs and skin. Moreover, an overview of the clinical course of the disease, including therapies, provides evidence for the therapeutic efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in inflammatory lung disease. Conclusions: We propose HCK-driven pulmonary and cutaneous vasculitis as a novel autoinflammatory disorder of inborn errors of immunity.

Links

90127, large research infrastructures
Name: CIISB II